Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab
- Indications Ulcerative colitis
- Focus Biomarker; Therapeutic Use
- Acronyms DETECT
- 17 Nov 2017 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.
- 17 Nov 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2018.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.